Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Doctors Divided Over Loss of Experimental Cholesterol Drug


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Alzheimer's Disease
Aneurysms
More...

Related Healthscout Videos
 border=
Howard: The Helping Hand for Stroke Survivors
Fixing Torn Hearts
Medicine's Next Big Thing? Growing Hearts
How can a supportive family help?
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Coronary Bypass Surgery
Erectile Dysfunction
More...

Related Drug Information
 border=
Accupril
Actonel
Altace
Avapro
More...

Related News Articles
 border=
'Tis the Season For Allergy, Asthma
FDA Report Says Nation's Health at Risk
High Blood Pressure Could Exacerbate Alzheimer's
Health Tip: The Road to a Healthy Heart
More...


Page:  << Prev | 1 | 2 | 3

Myerburg added, "I don't think there's any sense at this point of whether this is a class effect."

Heart patients still have other options, however, namely the cholesterol-lowering statins.

And, with the Pfizer study cut short, it's also unclear if torcetrapib would have turned out to be a blockbuster along the lines of Lipitor.

Text Continues Below



"There was no reason to think that there would be this kind of harm, but the other side of the coin is how much added benefit would this strategy have given to what we already have," Myerburg said. "There could have been a surprise there. We could have been wrong on the upside as well."

Perhaps the only good news for Pfizer is that the negative study results came out in pre-marketing studies, thus avoiding the litigation problems Merck & Co. is now facing with its derailed arthritis drug Vioxx.

The torcetrapib study was large enough to detect a relatively small number of problems. Usually such issues only surface when a drug is approved and marketed.

"Most studies aren't that big," Myerburg said. "This is a statement about the importance of doing adequately sized trials and of doing post-marketing studies. Cut this study in half, and you might have seen a benefit but missed the adverse effects."

More information

For more on cholesterol and heart disease, visit the American Heart Association (www.americanheart.org).

Page:  << Prev | 1 | 2 | 3

Copyright © 2006 ScoutNews, LLC. All rights reserved.
Last updated 12/4/2006

Related Links
 border=
From Healthscout's partner site on heart disease, MyHeartCentral.com
Learn about heart disease symptoms.
Get more information on heart disease treatment for your health!
What can you do to prevent heart disease? Prevention details here.





New Features

New ADHD Site!

SOURCES: Raymond Gibbons, M.D., president, American Heart Association, and professor of medicine, and co-director, Nuclear Cardiology Lab, Mayo Clinic, Rochester, Minn.; Daniel Fisher, M.D., clinical assistant professor of medicine, New York University School of Medicine, New York City; Robert J. Myerburg, M.D., professor of medicine and physiology, University of Miami School of Medicine; U.S. Food and Drug Administration statement, Dec. 4, 2006


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map